Capecitabine Market Size - By Indication (Breast, Colorectal, Gastric, Pancreatic), By Synthesis Type (Chemical Based API, Biological API, Highly Potent API, Mode, Global Forecast 2023- 2032
Published Date: July - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCapecitabine Market Size - By Indication (Breast, Colorectal, Gastric, Pancreatic), By Synthesis Type (Chemical Based API, Biological API, Highly Potent API, Mode, Global Forecast 2023- 2032
Capecitabine Market Size
Capecitabine Market size was valued to be USD 408.2 million in 2022 and is expected to reach USD 652.9 million in 2032 with a CAGR of 4.9% from 2023 to 2032 driven by a number of important factors, such as capecitabine has demonstrated significant clinical effectiveness in treating different cancer types over the years. It is particularly valued for its role in adjuvant therapy (post-surgery) and as a component of combination regimens for metastatic disease and hence its proven efficacy drives its use in cancer treatment.
Furthermore, the increasing global population susceptible to various cancer types such as colorectal cancer, breast cancer, and gastric cancer, serves as a significant driver of the capecitabine industry expansion. According to the report published by World Cancer Research Fund International, 2020 saw an estimated 18.1 million cancer cases worldwide, with breast cancers emerging as the most prevalent, contributing 12.5% to the total number of new diagnoses that year.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Capecitabine Market Size in 2022 | USD 408.2 Million |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 4.9% |
| 2032 Value Projection | USD 652.9 Million |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 162 |
| Tables, Charts & Figures | 235 |
| Segments covered | Indication, Synthesis Type, Mode, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
Capecitabine is a chemical compound used as the active pharmaceutical ingredients in formulations, particularly in the manufacturing of medications for cancer treatment. As an API, capecitabine is synthesized and formulated as tablets to be administered orally as part of cancer treatment regimens.
COVID-19 Impact
The COVID-19 pandemic took a big toll on businesses worldwide, especially early on. For the pharmaceutical industry, one of the biggest challenges was that many factories had to close down. This made it hard to get the active pharmaceutical ingredients (APIs) needed to make medicines. At first, things were tough for the API industry. Factories had fewer workers because of the pandemic, and it was harder to get supplies and packaging. But as the pandemic wore on, especially towards the end of 2020, the demand for certain medicines skyrocketed. This meant that there was also a huge increase in the demand for APIs. The pharmaceutical industry grew a lot during the pandemic because of this high demand for medications.
Capecitabine Market Driving Factors
Cancer is on the rise, and this is a major reason why the cancer industry is expected to grow. In fact, cancer has become a global health crisis, with more and more people being diagnosed with it every year. There are several factors driving this increase in cancer cases, including the fact that people are living longer, changes in our lifestyles, pollution, and the fact that we're getting better at detecting cancer. As a result of all these factors, the number of people who need cancer treatment is also growing. And since more people are being diagnosed with cancer, the demand for cancer drugs like capecitabine is also going up. For example, in the United States alone, the American Cancer Society predicts that nearly 2 million new cases of cancer will be diagnosed in 2023. Sadly, around 600,000 people in the U.S. are expected to die from cancer this year. That's about 1,670 people every day.
Capecitabine Restraint
Making capecitabine, a cancer-fighting drug, isn't easy. It's like a complicated recipe with many steps. Each step requires special equipment, chemicals, and lots of attention to make sure it's done just right. Since it's so complex, it takes skilled workers and fancy equipment, which makes it expensive to produce. And because capecitabine is used to treat cancer, it has to be super pure and safe. Manufacturers have to spend a lot on checking its quality, testing it, and making sure it meets all the rules. All of these things add up and make capecitabine more expensive to make.
Capecitabine Market Analysis
Based on the indication, the capecitabine market is segmented into breast cancer, colorectal cancer, gastric cancer, pancreatic cancer and other indications. The breast cancer segment is expected to reach USD 265.8 million by end of 2032. This leading market share is owing to the rising prescriptions of capecitabine for the treatment of metastatic breast cancer due to its proven efficacy. Capecitabine is an approved prodrug used for the treatment of metastatic breast cancer. It can be used as a single-agent chemotherapy or in combination with other chemotherapy drugs, such as docetaxel, Lapatinib, Oxaliplatin, Bevacizumab, etc.
The capecitabine market is divided into three main types based on how the drug is madechemical-based API, biological API, and highly potent API (HPAPI). In 2022, the chemical-based API segment was the biggest, making up 58.1% of all sales. It's expected to keep growing at a rate of 4.7% per year from 2023 to 2032. There's a big push in the pharmaceutical industry to make things more sustainably, including how chemical-based APIs are made. Companies are switching to green chemistry practices, cutting down on waste, and improving their processes to be better for the environment. Plus, drug companies are building new factories and buying new equipment to keep up with the growing demand for capecitabine and other cancer treatments. They're also coming up with new ways to make capecitabine that are more efficient and produce more of the drug.
Based on the mode, the global capecitabine market is fragmented into in-house manufacturing and contract manufacturing. The potential for progression in this sector is substantial, driven by the prominent trend of continuous process optimization. This trend focuses on enhancing efficiency, cutting down manufacturing expenses, and minimizing environmental footprints. To optimize capecitabine API production, manufacturers are applying efficient production techniques, automation, and enhanced process monitoring. Along with this, as demand for capecitabine and cancer medicines increases, pharmaceutical companies are increasing their in-house production capacity. This may entail building new facilities or improving current ones to meet rising production demands.
In the coming years, the North American market for the drug Capecitabine is expected to grow rapidly, reaching a value of $252.5 million by 2032. This growth is driven by a number of factors, including a strong network of pharmaceutical manufacturers in the region and a robust regulatory framework. In North America, there are many pharmaceutical companies that produce Capecitabine, both domestic and international. These companies must follow strict regulations set by the U.S. Food and Drug Administration (FDA) and Health Canada. This ensures that the Capecitabine produced in North America is safe, effective, and of high quality. North America is also a leader in cancer research. Many universities, research centers, and pharmaceutical companies in the region are conducting studies on Capecitabine and other cancer treatments. This research will help to improve the understanding of Capecitabine and its uses, which could lead to new treatments for cancer patients.
Capecitabine Market Share
Major players operating in the capecitabine is as mentioned below
- Sun Pharmaceutical Industries Ltd
- Shilpa Medicare limited
- Atom Pharma
- Global Calcium
- LGM Pharma
- Dr. Reddy’s Laboratories Ltd
- Cipla Ltd
- Zeon Pharma
- Avanscure Lifesciences Pvt Ltd
- Hepartex
Capecitabine Company Market Share Analysis
Industry share within this capecitabine market is influenced by various factors, including product quality, regulatory compliance, pricing strategies, and the ability to effectively manage demand fluctuations. Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd and Shilpa Medicare limited accounts for largest market share in the overall industry. Further, adherence to regulatory requirements, such as good manufacturing practices (GMP), is crucial for building and retaining customer trust.
Capecitabine Market Industry News
- In December 2022, Shilpa Medicare announced that it has introduced Capecitabine (Capebel) dispersible tablet (DT) with technology of faster dispersion within 90 seconds to treat colorectal and metastatic breast cancer. This product launch may help the company to enhance their product portfolio and enhance business revenue.
- In February 2021, Dr Reddy’s Laboratories announced the launch of Capecitabine Tablets, USP, in the U.S. market. The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA). This product launch helped the company to enhance their product portfolio and enhance their business revenue.
The capecitabine market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Indication
- Breast cancer
- Colorectal cancer
- Gastric cancer
- Pancreatic cancer
- Other indications
By Synthesis Type
- Chemical based API
- Biological API
- Highly potent API (HPAPI)
By Mode
- In-house manufacturing
- Contract manufacturing
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Malaysia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy